查看文章

A number of previously fatal neurological conditions have been rendered treatable, chronic conditions by advances in research. As clinicians delivering a diagnosis such as Parkinson’s disease (PD) to a concerned patient, we take solace in the knowledge that we have many symptomatic therapies to restore quality of life. Just as we consider the individual’s pertinent symptoms and comorbidities in selecting treatments, we must also consider the prevalence and impact of medication nonadherence. Previously referred to as medication compliance, the term “medication adherence” is preferred as it emphasizes patient autonomy and decision-making [1, 2]. Nonadherence is common, critical, and costly. Eight percent to 11% of hospitalizations in elderly patients are attributable to nonadherence, as is a twofold to sixfold increase in the risk of death within 1 year of a myocardial infarction [3–5]. Furthermore …